Prognosis of thyroid carcinoma.

T Harada, K Shimaoka, K Yakumaru, T Taniguchi, K Ito
{"title":"Prognosis of thyroid carcinoma.","authors":"T Harada,&nbsp;K Shimaoka,&nbsp;K Yakumaru,&nbsp;T Taniguchi,&nbsp;K Ito","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>With 612 cases of malignant thyroid tumor, the follow-up observations were conducted from 7 to 11 years after initial examination, and 512 cases were follow up. It was found that 46 cases died of the primary cancer, while 13 died of other causes. The prognosis proved to be favorable with adenocarcinoma but with anaplastic carcinoma or squamous cell carcinoma the disease proved to be ultimately fatal. The survival rates 5 and 10 years after diagnosis were 97.4% and 95.8% for papillary adenocarcinoma, 95.6% and 92.5% for follicular adenocarcinoma, 7.7% and 7.7% for anaplastic carcinoma, 0% for squamous cell carcinoma, and 66.9% and 66.9% for malignant lymphoma. As to the causes of death, the obstruction due to the neck tumor ranks first, indicating that respiratory deaths are numerous. However, as there are histologically many deaths due to the transformation from adenocarcinoma to squamous cell carcinoma or anaplastic carcinoma, it is desirable to perform radical surgery at an early stage.</p>","PeriodicalId":75934,"journal":{"name":"International advances in surgical oncology","volume":"4 ","pages":"83-110"},"PeriodicalIF":0.0000,"publicationDate":"1981-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International advances in surgical oncology","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

With 612 cases of malignant thyroid tumor, the follow-up observations were conducted from 7 to 11 years after initial examination, and 512 cases were follow up. It was found that 46 cases died of the primary cancer, while 13 died of other causes. The prognosis proved to be favorable with adenocarcinoma but with anaplastic carcinoma or squamous cell carcinoma the disease proved to be ultimately fatal. The survival rates 5 and 10 years after diagnosis were 97.4% and 95.8% for papillary adenocarcinoma, 95.6% and 92.5% for follicular adenocarcinoma, 7.7% and 7.7% for anaplastic carcinoma, 0% for squamous cell carcinoma, and 66.9% and 66.9% for malignant lymphoma. As to the causes of death, the obstruction due to the neck tumor ranks first, indicating that respiratory deaths are numerous. However, as there are histologically many deaths due to the transformation from adenocarcinoma to squamous cell carcinoma or anaplastic carcinoma, it is desirable to perform radical surgery at an early stage.

分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
甲状腺癌的预后。
612例甲状腺恶性肿瘤,自初检后随访7 ~ 11年,随访512例。结果发现,46例死于原发癌症,13例死于其他原因。腺癌的预后良好,但间变性癌或鳞状细胞癌的预后最终是致命的。诊断后5年和10年生存率分别为:乳头状腺癌97.4%和95.8%,滤泡性腺癌95.6%和92.5%,间变性癌7.7%和7.7%,鳞状细胞癌0%,恶性淋巴瘤66.9%和66.9%。至于死因,颈部肿瘤引起的梗阻排在第一位,说明呼吸系统死亡人数众多。然而,由于组织学上有许多死亡是由腺癌转化为鳞状细胞癌或间变性癌引起的,因此在早期进行根治性手术是可取的。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Carcinoma of the adrenal cortex: clinical description, diagnosis, and treatment. Monoclonal hybridoma antibodies in human melanoma: current status. Bone replacement in surgery of bone tumors. Management of locally advanced breast cancer (stage III): a review. Antibiotic coverage for bowel surgery.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1